Over 4,600 people have received second dose of AstraZeneca COVID-19 vaccine in Nigeria – NPHCDA
The National Primary Health Care Development Agency (NPHCDA) has disclosed that a total of 4,683 people have received the second dose of AstraZeneca COVID-19 vaccine in the country.
NPHCDA Executive Director, Dr Faisal Shuaib made the disclosure at a press conference to update Nigerians on the status of the vaccination exercise in Abuja on Tuesday May 25.
Revealing that the agency has almost completed administering all first doses as of Monday May 24, Shuaib also disclosed that 1,929,237 Nigerians have been captured so far, representing 96 per cent of the targeted population.
“We are advising that all Nigerians who have received their first dose should check their vaccination cards for the date of their second dose, and ensure that they receive the second dose to gain full protection against COVID-19.
“As we transition to administering second doses, our teams have assessed the communication and mobilisation activities that have been undertaken thus far to create awareness for the COVID-19 vaccine and encourage uptake.
“We will be building on the work we have already done in these areas to ensure that Nigerians can easily access accurate information about COVID-19 vaccination.”
The NPHCDA boss gave the assurance that the agency would continue engagement and communication with communities across the country, noting that the success recorded with the first dose was the collective efforts of all stakeholders.
Acknowledging the challenges of vaccine supply in the global community, he also hinted that Nigeria might receive the next consignment of vaccines by end of July or August.
“When we are able to, we will provide an update regarding timelines and details of the next shipment. At present, we do not have that information available due to the wider context we are in. However, we can update you on some positive developments.
“Pfizer and BioNTech pledged on Friday of last week to provide one billion doses of their COVID-19 vaccine to low-and-middle-income countries by the end of 2021, and another one billion doses in 2022.”
Written by admin